Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
CD79A Antibody (JCB117), Novus Biologicals™
Mouse Monoclonal Antibody
Supplier: Novus Biologicals NBP2329490.1MG
Description
CD79A Monoclonal specifically detects CD79A in Human samples. It is validated for Western Blot, Flow Cytometry, Immunohistochemistry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry-Paraffin.Specifications
CD79A | |
Monoclonal | |
Unconjugated | |
PBS with 0.05% BSA. with 0.05% Sodium Azide | |
CD79a antigen, CD79A antigen (immunoglobulin-associated alpha), CD79a molecule, immunoglobulin-associated alpha, IGAB-cell antigen receptor complex-associated protein alpha chain, Ig-alpha, MB1, MB-1, MB-1 membrane glycoprotein, Membrane-bound immunoglobulin-associated protein, Surface IgM-associated protein | |
Mouse | |
44 kDa | |
0.1 mg | |
Adaptive Immunity, Cell Biology, Immunology, Phospho Specific | |
973 | |
Human | |
Purified |
Western Blot, Flow Cytometry, Immunocytochemistry, Immunofluorescence, Immunoprecipitation, Immunohistochemistry (Paraffin) | |
JCB117 | |
Western Blot 0.5-1ug/ml, Flow Cytometry 0.5-1ug/million cells, Immunocytochemistry/Immunofluorescence 0.5-1ug/ml, Immunoprecipitation 0.5-1ug/500ug protein lysate, Immunohistochemistry-Paraffin 0.5-1.0ug/ml, Immunohistochemistry-Frozen 0.5-1.0ug/ml, SDS-Page | |
P11912 | |
CD79A | |
A synthetic peptide corresponding to aa 202-216 (GTYQDVGSLNIADVQ) of human CD79a protein. | |
Protein A purified | |
RUO | |
Primary | |
A disulphide-linked heterodimer, consisting of mb-1 (or CD79a) and B29 (or CD79b) polypeptides, is non-covalently associated with membrane-bound immunoglobulins on B cells. This complex of mb-1 and B29 polypeptides and immunoglobulin constitute the B cell Ag receptor. CD79a first appears at pre B cell stage, early in maturation, and persists until the plasma cell stage where it is found as an intracellular component. CD79a is found in the majority of acute leukemias of precursor B cell type, in B cell lines, B cell lymphomas, and in some myelomas. It is not present in myeloid or T cell lines. Anti-CD79a is generally used to complement anti-CD20 especially for mature B-cell lymphomas after treatment with Rituximab (anti-CD20). This antibody will stain many of the same lymphomas as anti-CD20, but also is more likely to stain B-lymphoblastic lymphoma/leukemia than is anti-CD20. Anti-CD79a also stains more cases of plasma cell myeloma and occasionally some types of endothelial cells as wel | |
Store at 4C. | |
IgG1 κ |
Provide Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?
Provide Content Correction